|
|
||||||||
Investigative Ophthalmology & Visual Science, Vol 38, 1761-1767, Copyright © 1997 by Association for Research in Vision and Ophthalmology
ARTICLES AND REPORTS |
P Zhu, JL Beny, J Flammer, TF Luscher and IO Haefliger
Laboratory of Ocular Pharmacology and Physiology, University Eye Hospital, Basel, Switzerland.
PURPOSE: To assess the effects of K(+)-channel blockers on bradykinin- induced relaxations in porcine ciliary artery. METHODS: Vascular isometric forces were measured with a myograph system. Ciliary vascular rings were precontracted with thromboxane A2 analog (U 46619, 10(-7) M) to assess dose-dependent (10(-10)-3 x 10(-6) M) bradykinin-induced relaxation after addition of one of the following: the nitric oxide (NO) synthase inhibitor N omega-nitro-L-arginine methyl ester (L-NAME, 10(-4) M) or inactive enantiomer (D-NAME, 10(-4) M); the nonspecific K(+)-channel blocker tetra-ethylammonium (TEA, 10(-2) M); or the ATP- sensitive K(+)-channel blocker glibenclamide (10(-5) M). The effect of TEA on relaxations to the NO donor, sodium nitroprusside (SNP, 10(-10)- 10(-4) M) was investigated. The membrane potential of vascular smooth muscle cells (VSMC) was recorded after exposure to bradykinin (2.5 x 10(-7) M). RESULTS: Endothelium-dependent relaxations to bradykinin (maximal [max], 99% +/- 3%) were strongly inhibited by L-NAME (max, 39% +/- 4%, P < 0.01) and partially by TEA (max, 62% +/- 3%, P < 0.01) or glibenclamide (max, 77% +/- 4%, P < 0.01). Administration of glibenclamide plus L-NAME further suppressed bradykinin-induced relaxation (max, 23% +/- 6%; P < 0.01), whereas TEA and L-NAME (max, 6% +/- 2%; P < 0.01) abolished the relaxation. SNP relaxations were unaffected by TEA. Bradykinin had no effect on the membrane potential of VSMC. CONCLUSIONS: In porcine ciliary artery, the endothelium- dependent relaxations to bradykinin are primarily mediated by NO and involve K(+)-channels. As only relaxations to bradykinin, but not those mediated by SNP, were inhibited by TEA, this implies that K(+)-channel blockers most likely affect the bradykinin-evoked NO production or release by the endothelium.
This article has been cited by other articles:
![]() |
I. Vysniauskiene, R. Allemann, J. Flammer, and I. O. Haefliger Vasoactive Responses of U46619, PGF2{alpha}, Latanoprost, and Travoprost in Isolated Porcine Ciliary Arteries Invest. Ophthalmol. Vis. Sci., January 1, 2006; 47(1): 295 - 298. [Abstract] [Full Text] [PDF] |
||||
![]() |
C Cleary, C H Buckley, E Henry, P McLoughlin, C O'Brien, and P W F Hadoke Enhanced endothelium derived hyperpolarising factor activity in resistance arteries from normal pressure glaucoma patients: implications for vascular function in the eye Br. J. Ophthalmol., February 1, 2005; 89(2): 223 - 228. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Tasatargil and G. Sadan Reduction in [D-Ala2, NMePhe4, Gly-ol5]Enkephalin-Induced Peripheral Antinociception in Diabetic Rats: The Role of the L-Arginine/Nitric Oxide/Cyclic Guanosine Monophosphate Pathway Anesth. Analg., January 1, 2004; 98(1): 185 - 192. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. S. Dettmann, I. Vysniauskiene, R. Wu, J. Flammer, and I. O. Haefliger Adrenomedullin-Induced Endothelium-Dependent Relaxation in Porcine Ciliary Arteries Invest. Ophthalmol. Vis. Sci., September 1, 2003; 44(9): 3961 - 3966. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Dumont, P. Hardy, K. G. Peri, X. Hou, S. Molotchnikoff, D. R. Varma, and S. Chemtob Regulation of endothelial nitric oxide synthase by PGD2 in the developing choroid Am J Physiol Heart Circ Physiol, January 1, 2000; 278(1): H60 - H66. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. Michel and F. E. Curry Microvascular Permeability Physiol Rev, July 1, 1999; 79(3): 703 - 761. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Hardy, D. Abran, X. Hou, I. Lahaie, K. G. Peri, P. Asselin, D. R. Varma, and S. Chemtob A Major Role for Prostacyclin in Nitric Oxide–Induced Ocular Vasorelaxation in the Piglet Circ. Res., October 5, 1998; 83(7): 721 - 729. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |